AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial
Portfolio Pulse from Vandana Singh
AC Immune SA (ACIU) is advancing its Alzheimer's targeting immunotherapy, ACI-35.030, into a Phase 2b trial. The trial will evaluate the treatment in patients with preclinical Alzheimer's disease. AC Immune will receive milestone payments totaling CHF 40 million from its development partner, Janssen Pharmaceuticals Inc, a Johnson & Johnson (JNJ) company. Additionally, AC Immune has priced an underwritten offering of 14.3 million shares at $3.50 each, raising $50.1 million. ACIU shares have risen 2.83% to $3.82.
December 15, 2023 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Johnson & Johnson, through its Janssen Pharmaceuticals division, is involved in the development of AC Immune's Alzheimer's immunotherapy and will be making milestone payments as the trial progresses.
While the news is positive for AC Immune, the financial impact on Johnson & Johnson is likely to be less significant due to the larger size and diversified nature of JNJ's operations. The milestone payments are part of an existing agreement and are unlikely to have a substantial short-term impact on JNJ's stock price.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
AC Immune is progressing with its Phase 2b trial for Alzheimer's immunotherapy and has raised $50.1 million through a share offering. The company's stock has increased following the news.
The advancement into a Phase 2b trial for ACI-35.030 and the successful capital raise are positive developments for AC Immune. The milestone payments from Janssen Pharmaceuticals provide additional financial support and validation of the company's research. These factors are likely to have a positive short-term impact on ACIU's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100